Reduction of annexin A5 anticoagulant ratio identifies antiphospholipid antibody-positive patients with adverse clinical outcomes

Journal of Thrombosis and Haemostasis

Volumn 15, Issue 7, 2017, Pages 1412-1421

  Wolgast, L R ^a   Arslan, A A ^b   Wu, X X ^c   Beyda, J N ^d   Pengo, V ^e   Rand, J H ^c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d MOUNT SINAI HOSPITAL   (United States)

^e UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Annexin A5; antiphospholipid antibodies; antiphospholipid syndrome; pregnancy complications; thrombosis

Indexed keywords

LIPOCORTIN 5; PHOSPHOLIPID ANTIBODY; ANTICOAGULANT AGENT; PHOSPHOLIPID;

ADULT; ADVERSE OUTCOME; AGED; ANNEXIN A5 ANTICOAGULANT RATIO; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD CLOTTING PARAMETERS; CONTROLLED STUDY; FEMALE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PREGNANCY COMPLICATION; PRIORITY JOURNAL; TERTIARY CARE CENTER; THROMBOSIS; VALIDATION PROCESS; VERY ELDERLY; ADOLESCENT; BLOOD; BLOOD CLOTTING; CASE CONTROL STUDY; CHEMISTRY; COHORT ANALYSIS; IMMUNOLOGY; MIDDLE AGED; PREGNANCY; SPONTANEOUS ABORTION; TREATMENT OUTCOME; YOUNG ADULT;

ABORTION, SPONTANEOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANNEXIN A5; ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; BLOOD COAGULATION; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHOLIPIDS; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; THROMBOSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85020480388     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13699     Document Type: Article

References (34)

1. Andreoli L, Chighizola CB, Banzato A, Pons-Estel GJ, de Jesus GR, Erkan D. The estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis. Arthritis Care Res (Hoboken) 2013; 65: 1869–73.
2. Moore JE, Mohr CF. Biologically false positive serological tests for syphilis: type, incidence, and cause. J Am Med Assoc 1952; 150: 467–73.
3. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, de Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306.
4. Flaherty MJ, West S, Heimark RL, Fujikawa K, Tait JF. Placental anticoagulant protein-I: measurement in extracellular fluids and cells of the hemostatic system. J Lab Clin Med 1990; 115: 174–81.
5. Krikun G, Lockwood CJ, Wu XX, Zhou XD, Guller S, Calandri C, Guha A, Nemerson Y, Rand JH. The expression of the placental anticoagulant protein, annexin V, by villous trophoblasts: immunolocalization and in vitro regulation. Placenta 1994; 15: 601–12.
6. Mosser G, Ravanat C, Freyssinet JM, Brisson A. Sub-domain structure of lipid-bound annexin-V resolved by electron image analysis. J Mol Biol 1991; 217: 241–5.
7. Voges D, Berendes R, Burger A, Demange P, Baumeister W, Huber R. Three-dimensional structure of membrane-bound annexin V. A correlative electron microscopy-X-ray crystallography study. J Mol Biol 1994; 238: 199–213.
8. Reviakine I, Bergsma-Schutter W, Brisson A. Growth of protein 2-D crystals on supported planar lipid bilayers imaged in situ by AFM. J Struct Biol 1998; 121: 356–61.
9. Rand JH, Wu XX, Quinn AS, Chen PP, McCrae KR, Bovill EG, Taatjes DJ. Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay. Am J Pathol 2003; 163: 1193–200.
10. Tomer A. Antiphospholipid antibody syndrome: rapid, sensitive, and specific flow cytometric assay for determination of anti-platelet phospholipid autoantibodies. J Lab Clin Med 2002; 139: 147–54.
11. Hanly JG, Smith SA. Anti-beta2-glycoprotein I (GPI) autoantibodies, annexin V binding and the anti-phospholipid syndrome. Clin Exp Immunol 2000; 120: 537–43.
12. Cederholm A, Svenungsson E, Jensen-Urstad K, Trollmo C, Ulfgren AK, Swedenborg J, Fei GZ, Frostegard J. Decreased binding of annexin V to endothelial cells: a potential mechanism in atherothrombosis of patients with systemic lupus erythematosus. Arterioscler Thromb Vasc Biol 2005; 25: 198–203.
13. Rand JH, Wu XX, Lapinski R, van Heerde WL, Reutelingsperger CP, Chen PP, Ortel TL. Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. Blood 2004; 104: 2783–90.
14. Ruffatti A, Del Ross T, Ciprian M, Bertero M, Sciascia S, Scarpato S, Montecucco C, Rossi S, Caramaschi P, Biasi D, Doria A, Rampudda M, Nuzzo M, Fischetti F, Picillo U, Brucato A, Salvan E, Pengo V, Meroni P. Risk factors for first thrombotic event in antiphospholipid antibody carriers: a prospective multicenter follow-up study. Ann Rheum Dis 2011; 70: 1083–6.
15. Pengo V, Ruffatti A, Legnani C, Testa S, Fierro T, Marongiu F, De Micheli V, Gresele P, Tonello M, Ghirarduzzi A, Bison E, Denas G, Banzato A, Padayattil JS, Iliceto S. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 2011; 118: 4714–8.
16. Sciascia S, Cosseddu D, Montaruli B, Kuzenko A, Bertero MT. Risk Scale for the diagnosis of antiphospholipid syndrome. Ann Rheum Dis 2011; 70: 1517–8.
17. de-Groot PG, Horbach DA, Derksen RH. Protein C and other cofactors involved in the binding of antiphospholipid antibodies: relation to the pathogenesis of thrombosis. Lupus 1996; 5: 488–93.
18. Atsumi T, Khamashta MA, Amengual O, Donohoe S, Mackie I, Ichikawa K, Koike T, Hughes GR. Binding of anticardiolipin antibodies to protein C via beta2-glycoprotein I (beta2-GPI): a possible mechanism in the inhibitory effect of antiphospholipid antibodies on the protein C system. Clin Exp Immunol 1998; 112: 325–33.
19. Bidot CJ, Jy W, Horstman LL, Huisheng H, Jimenez JJ, Yaniz M, Ahn YS. Factor VII/VIIa: a new antigen in the anti-phospholipid antibody syndrome. Br J Haematol 2003; 120: 618–26.
20. Ao W, Zheng H, Chen XW, Shen Y, Yang CD. Anti-annexin II antibody is associated with thrombosis and/or pregnancy morbidity in antiphospholipid syndrome and systemic lupus erythematosus with thrombosis. Rheumatol Int 2011; 31: 865–9.
21. Amengual O, Atsumi T, Khamashta MA, Tinahones F, Hughes GR. Autoantibodies against oxidized low-density lipoprotein in antiphospholipid syndrome. Br J Rheumatol 1997; 36: 964–8.
22. Ortona E, Capozzi A, Colasanti T, Conti F, Alessandri C, Longo A, Garofalo T, Margutti P, Misasi R, Khamashta MA, Hughes GR, Valesini G, Sorice M. Vimentin/cardiolipin complex as a new antigenic target of the antiphospholipid syndrome. Blood 2010; 116: 2960–7.
23. Alessandri C, Bombardieri M, Di Prospero L, Conigliaro P, Conti F, Labbadia G, Misasi R, Sorice M, Valesini G. Anti-lysobisphosphatidic acid antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus. Clin Exp Immunol 2005; 140: 173–80.
24. Caronti B, Calderaro C, Alessandri C, Conti F, Tinghino R, Palladini G, Valesini G. Beta2-glycoprotein I (beta2-GPI) mRNA is expressed by several cell types involved in anti-phospholipid syndrome-related tissue damage. Clin Exp Immunol 1999; 115: 214–9.
25. Forastiero RR, Martinuzzo ME, Broze GJ. High titers of autoantibodies to tissue factor pathway inhibitor are associated with the antiphospholipid syndrome. J Thromb Haemost 2003; 1: 718–24.
26. Yang CD, Hwang JC, Yan W, Gallagher K., FitzGerald J, Hahn BH, Chen PP. Identification of anti-plasmin antibodies in the antiphospholipid syndrome that inhibit degradation of fibrin. J Immunol 2004; 172: 5765–73.
27. Rand JH, Arslan AA, Wu XX, Wein R, Mulholland J, Shah M, van Heerde WL, Reutelingsperger CP, Lockwood CJ, Kuczynski E. Reduction of circulating Annexin A5 levels and resistance to Annexin A5 anticoagulant activity in women with recurrent spontaneous pregnancy losses. Am J Obstet Gynecol 2006; 194: 182–8.
28. Ruffatti A, Calligaro A, Hoxha A, Trevisanuto D, Ruffatti AT, Gervasi MT, Cuffaro S, Pengo V, Punzi L. Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome. Arthritis Care Res (Hoboken) 2010; 62: 302–7.
29. Pengo V, Ruffatti A, Legnani C, Gresele P, Barcellona D, Erba N, Testa S, Marongiu F, Bison E, Denas G, Banzato A, Padayattil JS, Iliceto S. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010; 8: 237–42.
30. Mateo J, Oliver A, Borrell M, Sala N, Fontcuberta J. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism–results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost 1997; 77: 444–51.
31. Jones JV, Eastwood BJ, Jones E, James H, Mansour M. Antiphospholipid antibodies in a healthy population: methods for estimating the distribution. J Rheumatol 1995; 22: 55–61.
32. Biggioggero M, Meroni PL. The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun Rev 2010; 9: A299–304.
33. Hughes GR, Khamashta MA. Seronegative antiphospholipid syndrome. Ann Rheum Dis 2003; 62: 1127.
34. McCarty GA. Seronegative APS (SNAPS) in 53 patients:seroconversion rate at 3.5 yrs [abstract]. J Autoimmun 2000; 1: OC35–A13.